Non-Small Cell Lung Cancer Therapeutics Market, By Therapy, By Distribution Channel, By Cancer Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

REPORT HIGHLIGHT

Non-Small Cell Lung Cancer Therapeutics Market size was valued at US$ 21,461.20 Million in 2024, expanding at a CAGR of 12.99% from 2025 to 2032.

Non-small cell lung cancer (NSCLC) therapeutics include a wide range of pharmacological and interventional interventions used in the treatment of lung cancers that do not qualify as small cell lung cancer. The therapeutic regimen for NSCLC has come a long way, going beyond the conventional use of chemotherapy to include targeted therapies that take advantage of specific tumour cell genetic mutations and immunotherapies that use the body's immunity against cancer. These therapies suppress cancer cell proliferation, trigger apoptosis (programmed cell death), and suppress metastasis. A therapeutic approach is selected based on factors such as the histological subtype of NSCLC, the stage of cancer at the time of diagnosis, the presence of specific biomarkers, and the patient's health status. The goal of therapy for NSCLC is to prolong survival, improve the quality of life, and palliate symptoms due to disease.

Non-Small Cell Lung Cancer Therapeutics Market- Market Dynamics

The market for non-small cell lung cancer therapeutics is driven by the propelling global incidence of lung cancer due to relentless smoking patterns and rising environmental pollution, which drives the need for efficient treatments. Lung cancer is a major cancer killer globally, according to the World Health Organization. Moreover, the rapid advances in unraveling the molecular underpinnings of NSCLC have opened the way for the rationale of creating targeted therapies and immunotherapies that promise more precise and potentially less toxic treatment. Further investigations into new biomarkers and targets for therapy have the promise to create more personalized medicine modalities. Combining immunotherapy with targeted agents yields encouraging results that enhance patient outcomes, especially in advanced disease.

In addition, the growing use of advanced diagnosis, such as liquid biopsies to identify and track response to early treatment, enables earlier and more effective treatments. The growth in healthcare infrastructure and the rising exposure to sophisticated cancer treatment in emerging markets also offer significant growth opportunities. However, the high price of several new therapies, especially targeted and immunotherapies, is a huge access barrier for a substantial share of the patient population worldwide. The complicated regulatory environment and the long, drawn-out approval process for new products can also hold back market expansion.

Non-Small Cell Lung Cancer Therapeutics Market- Key Insights

Targeted therapy has a substantial market share because it is highly effective in treating specific molecular subtypes of NSCLC, especially adenocarcinoma, the most common histologic subtype. Success with EGFR, ALK, and other actionable mutation-targeted drugs has made targeted therapy a mainstay of NSCLC therapy, resulting in enhanced progression-free survival in most patients with these alterations.

Immunotherapy is witnessing the most rapid expansion during the forecast period. This can be ascribed to its capability to yield durable responses and long-term survival benefits in a proportion of patients, even in advanced disease stages. Growing indications for immune checkpoint inhibitors, both in monotherapy and in combination with chemotherapy or targeted therapy, across various subtypes and stages of NSCLC are fueling this expansion.

Online pharmacies are projected to be the most rapidly growing distribution channel. The growth is fueled by increasing convenience, accessibility, and sometimes cost-effectiveness provided by online channels. Increased adoption of telemedicine and remote care services also enhances the growth of online pharmacies for oral NSCLC medication distribution.

Adenocarcinoma accounted for the largest market share as it is the world's most prevalent histological subtype of NSCLC and often presents with certain genetic mutations that are targetable with therapies presently available. Its larger prevalence and available targeted therapies have helped it become a leading player in the therapeutics market.

Non-Small Cell Lung Cancer Therapeutics Market- Segmentation Analysis:

The Global Non-Small Cell Lung Cancer Therapeutics Market is segmented on the basis of Therapy, Distribution Channel, Cancer Type, and Region.

By therapy, the market is segmented into targeted therapy, immunotherapy, and chemotherapy. Targeted therapy is the most significant share of the market. The dominance results from the vast improvement in realizing the molecular background of NSCLC, where identifying certain oncogenic drivers like EGFR, ALK, ROS1, and BRAF has become possible. The innovation and approval of successful drugs targeting these mutations have transformed the treatment model of patients carrying such changes, especially in adenocarcinoma. Targeted agents commonly demonstrate greater efficacy and better toxicity profiles than conventional chemotherapy in these particular patient groups and, hence, are a key element of initial and follow-up treatment protocols. Immunotherapy is the quickest-growing segment of the market. This fast growth is driven by the game-changing effect of immune checkpoint inhibitors, which have proven the capability to yield sustained responses and long-term survival in a proportion of patients with a range of NSCLC subtypes. Broadening immunotherapy indications to the earlier stages of the disease and combined with other modalities, such as chemotherapy and targeted therapy is further propelling market growth.

Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies are the biggest segment of the market. This segment has the greatest market share because of the type of treatment for NSCLC, which frequently includes the delivery of complicated intravenous therapy like chemotherapy and most immunotherapies. Hospitals have the required infrastructure, such as specialized infusion centers and skilled healthcare professionals, to deliver and monitor these treatments safely. In addition, hospital pharmacies are most often the initial dispensing point for drugs prescribed during an inpatient stay and for outpatients treated in specialized cancer centers. Online pharmacies are the most rapidly expanding sector in the market. The rise in take-up of e-commerce and the growing convenience provided by online websites are the reasons behind this expansion. Online drugstores give patients convenient access to oral drugs employed in treating NSCLC, including targeted treatments and certain supportive care medicines. They tend to have competitive prices and home delivery convenience, which can prove especially helpful for patients with ongoing conditions like lung cancer.

Non-Small Cell Lung Cancer Therapeutics Market- Geographical Insights

North America is the largest regional market for non-small cell lung cancer medicines. This is due to several factors, such as well-established healthcare infrastructure, high healthcare spending, and major pharmaceutical firms pushing innovation and early adoption of new medicines. The US has one of the highest rates of lung cancer and an effective regulatory infrastructure that allows for quick approval & adoption of new drugs. Furthermore, the strong focus on research and development, as well as positive reimbursement policies, adds to the leadership of North America. The Asia-Pacific region has the fastest growth for non-small cell lung cancer drugs. This rapid growth is largely the result of the huge and increasing patient base in markets such as China and India, the growing incidence of smoking and air pollution, and enhancing accessibility and affordability of healthcare. The ever-increasing rate of expenditure on healthcare infrastructure and the increasing rate of utilization of advanced cancer therapies such as immunotherapy & targeted therapy are also major growth drivers. Further, the rising number of clinical trials & development of local pharma industries are pushing the region's rapid growth.

Non-Small Cell Lung Cancer Therapeutics Market- Competitive Landscape:

The market for non-small cell lung cancer therapeutics is a highly competitive one with many entrenched pharma and biotech firms, as well as new entrants. Major players like Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, AstraZeneca, Pfizer Inc., Bristol Myers Squibb, and Merck Sharp & Dohme Corp. command large market shares fueled by the broad portfolios of approved treatments, research and development strengths, and established global distribution channels. These companies are developing new targeted therapies, immunotherapies, and combination regimens to address the evolving needs of NSCLC patients and overcome resistance to treatments. Strategic collaborations, licensing agreements, and buyouts also increased the competitive intensity to expand product pipelines and market coverage. Innovation is an area of differentiator, where firms are targeting the identification of new targets of therapy, next-generation inhibitors, and novel treatment approaches such as antibody-drug conjugates and cell therapies. The rising focus on personalized medicine and biomarker-based treatment approaches also generates competition, with firms investing in companion diagnostics to determine patient subsets most likely to respond to their therapies.

Recent Developments:

December 2024: AstraZeneca and Daiichi Sankyo reported that they had submitted a new biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of datopotamab deruxtecan (Dato-DXd) as a therapy for non-small cell lung cancer (NSCLC). The application is in adult patients previously treated with unresectable or metastatic NSCLC non-squamous.

October 2023: Eli Lilly and Company announced FDA approval of selpercatinib (Retevmo) in adult patients with a rearranged during transfection4 (RET) fusion-positive tumor detected by an FDA-approved test in locally advanced or metastatic non-small cell lung cancer. This approval adds to the treatment options for this molecular subtype of NSCLC, providing a targeted therapy with proven effectiveness.

June 2023: Bristol Myers Squibb reported on the FDA approval of Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant therapy followed by adjuvant monotherapy for nivolumab alone in adult patients with resectable (>=4 cm or node-positive) non-small cell lung cancer. This allows an additional dose of immunotherapy-based therapy in the perioperative setting for patients with more advanced resectable disease.

May 2023: Astellas collaborated with a biotech firm to discover and develop new antibody-drug conjugates targeting multiple cancers, including NSCLC. The collaboration will combine Astellas' expertise in antibody engineering with the partner's proprietary payload technology to develop more effective and targeted treatments for lung cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Genentech, Inc. (F. Hoffmann-La Roche Ltd)
Eli Lilly and Company
Celgene Corporation
AstraZeneca
Pfizer Inc.
Sanofi
Novartis AG
Astellas
Bristol Myers Squibb
Boehringer Ingelheim Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. (Takeda)
Merck Sharp & Dohme Corp.

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY - MARKET ANALYSIS, 2019 - 2032

Targeted Therapy
Immunotherapy
Chemotherapy

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL - MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032

Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5369

1. Non-Small Cell Lung Cancer Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Therapy
- 2.1.2. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Distribution Channel
- 2.1.3. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Cancer Type
- 2.1.4. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Country
- 2.1.5. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. Non-Small Cell Lung Cancer Therapeutics Key Market Trends

3.1. Non-Small Cell Lung Cancer Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Non-Small Cell Lung Cancer Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Non-Small Cell Lung Cancer Therapeutics Market Opportunities
3.4. Non-Small Cell Lung Cancer Therapeutics Market Future Trends

4. Non-Small Cell Lung Cancer Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Non-Small Cell Lung Cancer Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Non-Small Cell Lung Cancer Therapeutics Market Landscape

6.1. Non-Small Cell Lung Cancer Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Non-Small Cell Lung Cancer Therapeutics Market - By Therapy

7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapy, 2024 & 2032 (%)
- 7.1.2. Targeted Therapy
- 7.1.3. Immunotherapy
- 7.1.4. Chemotherapy

8. Non-Small Cell Lung Cancer Therapeutics Market - By Distribution Channel

8.1. Overview
- 8.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 8.1.2. Hospital Pharmacies
- 8.1.3. Retail Pharmacies
- 8.1.4. Online Pharmacies

9. Non-Small Cell Lung Cancer Therapeutics Market - By Cancer Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
- 9.1.2. Adenocarcinoma
- 9.1.3. Squamous Cell Carcinoma
- 9.1.4. Large Cell Carcinoma

10. Non-Small Cell Lung Cancer Therapeutics Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Non-Small Cell Lung Cancer Therapeutics Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- 11.2.2. Eli Lilly and Company
- 11.2.3. Celgene Corporation
- 11.2.4. AstraZeneca
- 11.2.5. Pfizer Inc.
- 11.2.6. Sanofi
- 11.2.7. Novartis AG
- 11.2.8. Astellas
- 11.2.9. Bristol Myers Squibb
- 11.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
- 11.2.11. Millennium Pharmaceuticals, Inc. (Takeda)
- 11.2.12. Merck Sharp & Dohme Corp.

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us